Life-threatening, invasive fungal infections cause over 3.75 million deaths worldwide and are a growing public health concern, particularly in immunocompromised individuals.
There are currently no fungal vaccines or immunotherapeutics approved for clinical use.
NXT Biologics is addressing this problem by developing a First-in-Class anti-fungal vaccine and monoclonal antibodies that prevent and treat infections due to multiple fungal pathogens.
Learn More About Our Science
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.